264 related articles for article (PubMed ID: 19994539)
1. AAPM recommendations on dose prescription and reporting methods for permanent interstitial brachytherapy for prostate cancer: report of Task Group 137.
Nath R; Bice WS; Butler WM; Chen Z; Meigooni AS; Narayana V; Rivard MJ; Yu Y;
Med Phys; 2009 Nov; 36(11):5310-22. PubMed ID: 19994539
[TBL] [Abstract][Full Text] [Related]
2. Comment on the "AAPM recommendations on dose prescription and reporting methods for permanent interstitial brachytherapy for prostate cancer: Report of Task Group 137" [Med. Phys. 36, 5310-5322 (2009)].
Merrick GS; Blasko JC
Med Phys; 2010 Jan; 37(1):404. PubMed ID: 20175504
[No Abstract] [Full Text] [Related]
3. Correlation between real-time intraoperative and postoperative dosimetry and its implications on intraoperative planning.
Yan C; Huq MS; Heron DE; Beriwal S; Wynn RB
Brachytherapy; 2019; 18(3):338-347. PubMed ID: 30655047
[TBL] [Abstract][Full Text] [Related]
4. Effect of edema associated with 131Cs prostate permanent seed implants on dosimetric quality indices.
Kehwar TS; Jones HA; Huq MS; Beriwal S; Benoit RM; Smith RP
Med Phys; 2009 Aug; 36(8):3536-42. PubMed ID: 19746787
[TBL] [Abstract][Full Text] [Related]
5. A survey of physics and dosimetry practice of permanent prostate brachytherapy in the United States.
Prete JJ; Prestidge BR; Bice WS; Friedland JL; Stock RG; Grimm PD
Int J Radiat Oncol Biol Phys; 1998 Mar; 40(4):1001-5. PubMed ID: 9531387
[TBL] [Abstract][Full Text] [Related]
6. Influence of source batch S dispersion on dosimetry for prostate cancer treatment with permanent implants.
Nuñez-Cumplido E; Perez-Calatayud J; Casares-Magaz O; Hernandez-Armas J
Med Phys; 2015 Aug; 42(8):4933-40. PubMed ID: 26233219
[TBL] [Abstract][Full Text] [Related]
7. A dynamic model for the estimation of optimum timing of computed tomography scan for dose evaluation of 125I or 103Pd seed implant of prostate.
Yue N; Dicker AP; Corn BW; Nath R; Waterman FM
Int J Radiat Oncol Biol Phys; 1999 Jan; 43(2):447-54. PubMed ID: 10030274
[TBL] [Abstract][Full Text] [Related]
8. Optimum timing for image-based dose evaluation of 125I and 103PD prostate seed implants.
Yue N; Chen Z; Peschel R; Dicker AP; Waterman FM; Nath R
Int J Radiat Oncol Biol Phys; 1999 Nov; 45(4):1063-72. PubMed ID: 10571216
[TBL] [Abstract][Full Text] [Related]
9. Comparison of MRI- and CT-based post-implant dosimetric analysis of transperineal interstitial permanent prostate brachytherapy.
Prete JJ; Prestidge BR; Bice WS; Dubois DF; Hotchkiss LA
Radiat Oncol Investig; 1998; 6(2):90-6. PubMed ID: 9572685
[TBL] [Abstract][Full Text] [Related]
10. Prescription dose in permanent (131)Cs seed prostate implants.
Yue N; Heron DE; Komanduri K; Huq MS
Med Phys; 2005 Aug; 32(8):2496-502. PubMed ID: 16193779
[TBL] [Abstract][Full Text] [Related]
11. Sensitivity of clinically relevant dosimetric parameters to contouring uncertainty in postimplant dosimetry of low-dose-rate prostate permanent seed brachytherapy.
Mashouf S; Safigholi H; Merino T; Soliman A; Ravi A; Morton G; Song WY
Brachytherapy; 2016; 15(6):774-779. PubMed ID: 27720310
[TBL] [Abstract][Full Text] [Related]
12. Coupling I-125 permanent implant prostate brachytherapy Monte Carlo dose calculations with radiobiological models.
Miksys N; Haidari M; Vigneault E; Martin AG; Beaulieu L; Thomson RM
Med Phys; 2017 Aug; 44(8):4329-4340. PubMed ID: 28455849
[TBL] [Abstract][Full Text] [Related]
13. Recommendations for intraoperative mesh brachytherapy: Report of AAPM Task Group No. 222.
Feng W; Rivard MJ; Carey EM; Hearn RA; Pai S; Nath R; Kim Y; Thomason CL; Boyce DE; Zhang H
Med Phys; 2021 Nov; 48(11):e969-e990. PubMed ID: 34431524
[TBL] [Abstract][Full Text] [Related]
14. Response to "Comment on 'AAPM recommendations on dose prescription and reporting methods for permanent interstitial brachytherapy for prostate cancer: report of Task Group 137'" [Med. Phys. 36, 5310-5322 (2009)].
Nath R; Bice WS; Butler WM; Chen Z; Meigooni AS; Narayana V; Rivard MJ; Yu Y
Med Phys; 2010 Apr; 37(4):1933. PubMed ID: 20443515
[No Abstract] [Full Text] [Related]
15. Edema-induced increase in tumour cell survival for 125I and 103Pd prostate permanent seed implants--a bio-mathematical model.
Yue N; Chen Z; Nath R
Phys Med Biol; 2002 Apr; 47(7):1185-204. PubMed ID: 11996063
[TBL] [Abstract][Full Text] [Related]
16. Recommendations of the American Association of Physicists in Medicine regarding the impact of implementing the 2004 task group 43 report on dose specification for 103Pd and 125I interstitial brachytherapy.
Williamson JF; Butler W; Dewerd LA; Huq MS; Ibbott GS; Mitch MG; Nath R; Rivard MJ; Todor D;
Med Phys; 2005 May; 32(5):1424-39. PubMed ID: 15984693
[TBL] [Abstract][Full Text] [Related]
17. Update of AAPM Task Group No. 43 Report: A revised AAPM protocol for brachytherapy dose calculations.
Rivard MJ; Coursey BM; DeWerd LA; Hanson WF; Huq MS; Ibbott GS; Mitch MG; Nath R; Williamson JF
Med Phys; 2004 Mar; 31(3):633-74. PubMed ID: 15070264
[TBL] [Abstract][Full Text] [Related]
18. Phase II study of intraoperative dosimetry for prostate brachytherapy using registered ultrasound and fluoroscopy.
Lee J; Hobbs RF; Zahurak M; Ng SK; Zhang Z; Burdette EC; DeWeese TL; Song DY
Brachytherapy; 2018; 17(6):858-865. PubMed ID: 30217432
[TBL] [Abstract][Full Text] [Related]
19. A detailed radiobiological and dosimetric analysis of biochemical outcomes in a case-control study of permanent prostate brachytherapy patients.
Butler WM; Stewart RR; Merrick GS
Med Phys; 2009 Mar; 36(3):776-87. PubMed ID: 19378738
[TBL] [Abstract][Full Text] [Related]
20. A comparative study of seed localization and dose calculation on pre- and post-implantation ultrasound and CT images for low-dose-rate prostate brachytherapy.
Ali I; Algan O; Thompson S; Sindhwani P; Herman T; Cheng CY; Ahmad S
Phys Med Biol; 2009 Sep; 54(18):5595-611. PubMed ID: 19717887
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
